Aggregation-Prone Motifs in Human Immunoglobulin G

Journal of Molecular Biology

Volumn 391, Issue 2, 2009, Pages 404-413

  Chennamsetty, Naresh ^a   Helk, Bernhard ^b   Voynov, Vladimir ^a   Kayser, Veysel ^a   Trout, Bernhardt L ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

antibody; genetic engineering; molecular simulation; protein; therapeutics

Indexed keywords

IMMUNOGLOBULIN A1 ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; DRUG INDICATION; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN MOTIF; PROTEIN TERTIARY STRUCTURE;

EID: 67650683480     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.06.028     Document Type: Article

References (39)

1. Carter P.J. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6 (2006) 343-357
2. Aggarwal S. What's fueling the biotech engine?-2007. Nat. Biotechnol. 26 (2008) 1227-1233
3. Shire S.J., Shahrokh Z., and Liu J. Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 93 (2004) 1390-1402
4. Kessler M., Goldsmith D., and Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol. Dial. Transplant. 21 (2006) v9-v12
5. Hermeling S., Crommelin D.J.A., Schellekens H., and Jiskoot W. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21 (2004) 897-903
6. Braun A., Kwee L., Labow M.A., and Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice. Pharm. Res. 14 (1997) 1472-1478
7. Caflisch A. Computational models for the prediction of polypeptide aggregation propensity. Curr. Opin. Chem. Biol. 10 (2006) 437-444
8. Chiti F., and Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 75 (2006) 336-366
9. Chiti F., Stefani M., Taddei N., Ramponi G., and Dobson C.M. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424 (2003) 805-808
10. Tartaglia G.G., Cavalli A., Pellarin R., and Caflisch A. Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci. 14 (2005) 2723-2734
11. Fernandez-Escamilla A.M., Rousseau F., Schymkowitz J., and Serrano L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat. Biotechnol. 22 (2004) 1302-1306
12. Trovato A., Chiti F., Maritan A., and Seno F. Insight into the structure of amyloid fibrils from the analysis of globular proteins. PLoS Comput. Biol. 2 (2006) 1608-1618
13. Cellmer T., Bratko D., Prausnitz J.M., and Blanch H.W. Protein aggregation in silico. Trends Biotechnol 25 (2007) 254-261
14. Nguyen H.D., and Hall C.K. Molecular dynamics simulations of spontaneous fibril formation by random-coil peptides. Proc. Natl Acad. Sci. USA 101 (2004) 16180-16185
15. Gsponer J., Haberthur U., and Caflisch A. The role of side-chain interactions in the early steps of aggregation: molecular dynamics simulations of an amyloid-forming peptide from the yeast prion Sup35. Proc. Natl Acad. Sci. USA 100 (2003) 5154-5159
16. 16-22 amyloid peptides into antiparallel β-sheets. Structure 11 (2003) 295-307
17. Harrison P.M., Chan H.S., Prusiner S.B., and Cohen F.E.J. Thermodynamics of model prions and its implications for the problem of prion protein folding. Mol. Biol. 286 (1999) 593-606
18. Dima R.I., and Thirumalai D. Exploring protein aggregation and self-propagation using lattice models: phase diagram and kinetics. Protein Sci. 11 (2002) 1036-1049
19. Broglia R.A., Tiana G., Pasqali S., Roman H.E., and Vigezzi E. Folding and aggregation of designed proteins. Proc. Natl Acad. Sci. USA 95 (1998) 12930-12933
20. Noon W.H., Kong Y., and Ma J. Molecular dynamics analysis of a buckyball-antibody complex. Proc. Natl Acad. Sci. USA 99 (2002) 6466-6470
21. Sinha N., and Smith-Gill S.J. Molecular dynamics simulation of a high-affinity antibody-protein complex: the binding site is a mosaic of locally flexible and preorganized rigid regions. Cell Biochem. Biophys. 43 (2005) 253-273
22. Chennamsetty, N., Voynov, V., Kayser, V., Helk B. & Trout, B. L. Design of therapeutic proteins with enhanced stability, Proc. Natl Acad. Sci. USA, doi:10.1073/pnas.0904191106.
23. Chennamsetty, N., Voynov, V., Kayser, V., Helk B. & Trout, B. L. Prediction of protein aggregation prone regions, Biophys. J. submitted for publication.
24. Baynes B.M., and Trout B.L. Rational design of solution additives for the prevention of protein aggregation. Biophys. J. 87 (2004) 1631-1639
25. Baynes B.M., Wang D.I., and Trout B.L. Role of arginine in the stabilization of proteins against aggregation. Biochemistry 44 (2005) 4919-4925
26. Dill K.A. Dominant forces in protein folding. Biochemistry 31 (1990) 7134-7155
27. Guharoy M., and Chakrabarti P. Conservation and relative importance of residues across protein-protein interfaces. Proc. Natl Acad. Sci. USA 43 (2005) 15447-15452
28. Jones S., and Thornton J.M. Principles of protein-protein interactions. Proc. Natl Acad. Sci. USA 93 (1996) 13-20
29. Young L., Jernigan R.L., and Covell D.G. A role for surface hydrophobicity in protein-protein recognition. Protein Sci. 3 (1994) 717-729
30. Tsai C., Lin S.L., Wolfson H.J., and Nussinov R. Studies of protein-protein interfaces: a statistical analysis of the hydrophobic effect. Protein Sci. 6 (1997) 53-64
31. Conte L.L., Chothia C., and Janin J. The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285 (1999) 2177-2198
32. DeLano W.L., Ultsch M.H., de Vos A.M., and Wells J.A. Convergent solutions to binding at a protein-protein interface. Science 287 (2000) 1279-1283
33. Black S.D., and Mould D.R. Development of hydrophobicity parameters to analyze proteins which bear post- or cotranslational modifications. Anal. Biochem. 193 (1991) 72-82
34. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 293 (2001) 1155-1159
35. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., and Karplus M. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J. Comput. Chem. 4 (1983) 187-217
36. Phillips J.C., Braun R., Wang W., Gumbart J., Tajkhorshid E., Villa E., et al. Scalable molecular dynamics with NAMD. J. Comput. Chem. 26 (2005) 1781-1802
37. MacKerell Jr. A.D., Bashford D., Bellott M., Dunbrack Jr. R.L., Evanseck J.D., Field M.J., et al. All-atom empirical potential for molecular modeling and dynamics Studies of protein. J. Phys. Chem. B 102 (1998) 3586-3616
38. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., and Klein M.L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79 (1983) 926-935
39. Kuttel M., Brady J.W., and Naidoo K.J. Carbohydrate solution simulations: producing a force field with experimentally consistent primary alcohol rotational frequencies and populations. J. Comput. Chem. 23 (2002) 1236-1243